Literature DB >> 16814608

Chemokine scavenging by D6: a movable feast?

Gerard J Graham1, Clive S McKimmie.   

Abstract

The atypical chemokine receptor, D6, is efficient at sequestering and scavenging inflammatory CC chemokines. The absence of D6 blocks the successful resolution of immune responses in models of inflammation, suggesting that CC-chemokine scavenging by D6 is an important component of the resolution phase of in vivo inflammatory responses. Most studies have suggested that lymphatic endothelial cells are the main vehicles for D6 function in vivo. Here, we propose that leukocytes, which also express D6, could be more-effective vehicles for D6 scavenging function. Thus, leukocytes might be the primary cell type that removes inflammatory chemokines from inflamed tissues. We also propose that lymphatic endothelial cell-expressed D6 might have a distinct but complementary role in restricting inflammatory leukocyte access to the lymphatic vasculature.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16814608     DOI: 10.1016/j.it.2006.06.006

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  17 in total

1.  Adaptive evolution of formyl peptide receptors in mammals.

Authors:  Yoshinori Muto; Stéphane Guindon; Toshiaki Umemura; László Kőhidai; Hiroshi Ueda
Journal:  J Mol Evol       Date:  2015-01-28       Impact factor: 2.395

2.  N-formyl peptide receptor 3 (FPR3) departs from the homologous FPR2/ALX receptor with regard to the major processes governing chemoattractant receptor regulation, expression at the cell surface, and phosphorylation.

Authors:  Marie-Josèphe Rabiet; Laurence Macari; Claes Dahlgren; François Boulay
Journal:  J Biol Chem       Date:  2011-05-04       Impact factor: 5.157

3.  The chemokine receptor D6 has opposing effects on allergic inflammation and airway reactivity.

Authors:  Gregory S Whitehead; Tie Wang; Laura M DeGraff; Jeffrey W Card; Sergio A Lira; Gerard J Graham; Donald N Cook
Journal:  Am J Respir Crit Care Med       Date:  2006-11-09       Impact factor: 21.405

Review 4.  Chemokines and chemokine receptors: standing at the crossroads of immunobiology and neurobiology.

Authors:  Richard M Ransohoff
Journal:  Immunity       Date:  2009-11-20       Impact factor: 31.745

5.  The C5a receptor (C5aR) C5L2 is a modulator of C5aR-mediated signal transduction.

Authors:  Claire E Bamberg; Charles R Mackay; Hyun Lee; David Zahra; Jenny Jackson; Yun Si Lim; Peter L Whitfeld; Stewart Craig; Erin Corsini; Bao Lu; Craig Gerard; Norma P Gerard
Journal:  J Biol Chem       Date:  2009-12-31       Impact factor: 5.157

Review 6.  Potential combinatorial effects of recombinant atypical chemokine receptors in breast cancer cell invasion: A research perspective.

Authors:  Ai Lan Chew; Wee Yee Tan; Boon Yin Khoo
Journal:  Biomed Rep       Date:  2013-01-21

Review 7.  DARC and D6: silent partners in chemokine regulation?

Authors:  Chris A H Hansell; Catherine E Hurson; Robert J B Nibbs
Journal:  Immunol Cell Biol       Date:  2010-12-14       Impact factor: 5.126

8.  Site-directed mutagenesis of the CC chemokine binding protein 35K-Fc reveals residues essential for activity and mutations that increase the potency of CC chemokine blockade.

Authors:  Gemma E White; Eileen McNeill; Ivy Christou; Keith M Channon; David R Greaves
Journal:  Mol Pharmacol       Date:  2011-05-17       Impact factor: 4.436

9.  D6 facilitates cellular migration and fluid flow to lymph nodes by suppressing lymphatic congestion.

Authors:  Kit Ming Lee; Clive S McKimmie; Derek S Gilchrist; Kenneth J Pallas; Robert J Nibbs; Paul Garside; Victoria McDonald; Christopher Jenkins; Richard Ransohoff; Liping Liu; Simon Milling; Vuk Cerovic; Gerard J Graham
Journal:  Blood       Date:  2011-10-06       Impact factor: 25.476

10.  Atypical chemokine receptor D6 inhibits human non-small cell lung cancer growth by sequestration of chemokines.

Authors:  Feng Ying Wu; Jiang Fan; Liang Tang; Yin Min Zhao; Cai Cun Zhou
Journal:  Oncol Lett       Date:  2013-05-21       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.